NEW YORK (GenomeWeb) – Swedish drug discovery firm Pelago Bioscience and German proteomics firm OmicScouts today announced a collaboration to determine and quantify drug interactions using Pelago's cellular thermal shift assay (CETSA) technology.

Under the terms of the agreement, Pelago has licensed its CETSA technology to OmicScouts for mass spectrometric and proteomic applications for contract research projects. The firms will combine expertise and resources to offer target identification and validation services.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.